Evolution of multiple disease screening in Keelung: A model for community involvement in health interventions?

Journal of Medical Screening

Volumn 13, Issue SUPPL.1, 2006, Pages

  Wang, Po En ^a   Wang, Ting Ting ^a   Chiu, Yueh Hsia ^a   Yen, Amy Ming Fang ^a   Chen, Tony Hsiu Hsi ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BREAST TUMOR; COMMUNITY CARE; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; HUMAN; LIVER TUMOR; MALE; MASS SCREENING; METHODOLOGY; MIDDLE AGED; MOUTH TUMOR; NEOPLASM; SOCIAL CLASS; STANDARD; STATISTICS; TAIWAN; UTERINE CERVIX TUMOR;

ADULT; AGED; BREAST NEOPLASMS; COMMUNITY HEALTH SERVICES; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MASS SCREENING; MIDDLE AGED; MOUTH NEOPLASMS; NEOPLASMS; SOCIAL CLASS; TAIWAN; UTERINE CERVICAL NEOPLASMS;

EID: 34247267670     PISSN: 09691413     EISSN: 14755793     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Chen THH, Chiu YH, Luh DL, et al. Community-based multiple screening model: design, implementation and analysis of 42,387 participants, Taiwan Community-Based Integrated Screening Group. Cancer 2004;100:1734-43
2. World Health Organisation. Declaration of Alma-Ata, 1978. www.who.dk/AboutWHO/Policy
3. Freedman DA, Petitti DB, Robins JM. On the efficacy of screening for breast cancer. Int J Epidemiol 2004;33:43-55 (Pubitemid 38500152)
4. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004;130:417-22
5. Mandel JS, Church TR, Bond JH, et al. The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med 2000;343:1603-7 (Pubitemid 32162983)
6. Sasieni P, Adams J, Cuzick J. Benefit of cervical screening at different ages: evidence from the UK audit of screening histories. Br J Cancer 2003;89:88-93 (Pubitemid 36897941)
7. Sankaranarayanan R, Ramadas K, Thomas G, et al. Effect of screening on oral cancer mortality in Kerala, India: a cluster-randomised controlled trial. Lancet 2005;365:1927-33 (Pubitemid 40797502)
8. CDC Diabetes Cost-Effectiveness Study Group. The cost-effectiveness of screening for type 2 diabetes. JAMA 1998;280:1757-63
9. Littenberg B, Garber AM, Sox HC. Screening for hypertension. Ann Intern Med 1990;112:192-202 (Pubitemid 20045209)
10. Littenberg B. A practice guideline revisited: screening for hypertension. Ann Intern Med 1995;122:937-9
11. Kuo HS, Chang HJ, Chou P, Teng L, Chen TH. A Markov chain model to assess the efficacy of screening for non-insulin dependent diabetes mellitus (NIDDM). Int J Epidemiol 1999;28:233-40 (Pubitemid 29176649)
12. Wong JM, Yen MF, Lai MS, Duffy SW, Smith RA, Chen TH. Progression rates of colorectal cancer by Dukes' stage in a high-risk group: analysis of selective colorectal cancer screening. Cancer J 2004;10:160-9 (Pubitemid 44313560)
13. Shiu MN, Chen TH. Intervention efficacy and malignant transformation to oral cancer among patients with leukoplakia. Oncol Rep 2003;10:1683-92
14. Tabar L, Vitak B, Chen HH, et al. The Swedish two-county trial twenty years later - updated mortality results and new insights from long-term follow-up. Radiol Clin N Am 2000;38:625-51 (Pubitemid 30640056)
15. Mandel JS, Bond JH, Church TR, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med 1993;328:1365-71 (Pubitemid 23131388)
16. Yoshinaga M, Motomura S, Takeda H, Yanagisawa Z, Ikeda K. Evaluation of the sensitivity of an immunochemical fecal occult blood test for colorectal neoplasia. Am J Gastroenterol 1995;90:1076-9
17. CDC Diabetes Cost-Effectiveness Study Group. The cost-effectiveness of screening for type 2 diabetes. JAMA 1998;280:1757-63
18. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. Br Med J 2003;326:1419